AZ’s Imfinzi joins the immunotherapy contest – pharmaphorum
|
AZ's Imfinzi joins the immunotherapy contest
pharmaphorum The US regulator has approved AstraZeneca's cancer immunotherapy, durvalumab – a blockbuster hopeful that could be the cornerstone of its new generation of oncology treatments. Under the brand name Imfinzi, durvalumab's first FDA-approved use will be … |
